A Study of Efficacy and Safety of Eltoprazine HCl for Treating Levodopa-induced Dyskinesia in Parkinson's Disease Patients

Exclusion Criteria

• •inability to use the motion sensors or electronic diaries correctly
• •surgical treatment for PD, e.g. Deep Brain Stimulation, within the last six months or planned during the study
• •unstable co-existing psychiatric disease including psychosis, depression or cognitive impairment
• •Mini Mental State Examination score of \<24
• •moderate or severe renal, or severe hepatic, impairment
• •treatment with selective serotonin re-uptake inhibitors (SSRI) or any combined serotonin-norepinephrine re-uptake inhibitors (SNRI), such as tryptizol, citalopram, escitalopram, sertraline, mianserin, mirtazapin, paroxetin, venlafaxine and St John's Wort, within four weeks prior to the Screening Visit
• •treatment with medications with the potential for drug-interactions (MAO-A inhibitors, apomorphine, aripiprazol, carbamazepine, clozapine, phenytoin, tramadol, quetiapine, varfaine, valproic acid). Patients taking amantadine will comprise no more than 25% of the study population
• •current history of a clinically significant and uncontrolled medical condition that may affect the safety of the patient or preclude adequate participation in the study
• •pregnant or breast-feeding
• •received any other investigational medicinal product within 30 days of Screening